ADHERENCE TO CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR MODULATOR THERAPIES, HOSPITALIZATIONS, AND MEDICAL COSTS IN PATIENTS WITH CYSTIC FIBROSIS USING MARKETSCAN COMMERCIAL CLAIMS AND ENCOUNTERS DATABASE

被引：0
|
作者：
Zhou, J. [1 ]
Witt, E. [1 ]
Hira, N. [2 ]
机构：
[1] Walgreen Co, Deerfield, IL USA
[2] AllianceRx Walgreens Prime, Orlando, FL USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR166
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [1] Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies
    Anwar, Saba
    Peng, Jin-Liang
    Zahid, Kashif Rafiq
    Zhou, Yu-Ming
    Ali, Qurban
    Qiu, Chong-Rong
    [J]. ADVANCES IN RESPIRATORY MEDICINE, 2024, 92 (04) : 263 - 277
  • [2] Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis
    Ramsey, Mitchell L.
    Gokun, Yevgeniya
    Sobotka, Lindsay A.
    Wellner, Michael R.
    Porter, Kyle
    Kirkby, Stephen E.
    Li, Susan S.
    Papachristou, Georgios I.
    Krishna, Somashekar G.
    Stanich, Peter P.
    Hart, Phil A.
    Conwell, Darwin L.
    Lara, Luis F.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (12): : 2446 - 2454
  • [3] Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies
    Carbone, Annalucia
    Vitullo, Pamela
    Di Gioia, Sante
    Conese, Massimo
    [J]. GENES, 2023, 14 (10)
  • [4] Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies
    Antoniu, Sabina Antonela
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 423 - 425
  • [5] ADHERENCE TO BIOLOGICS, HOSPITALIZATIONS, AND MEDICAL COSTS IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE USING THE MARKETSCAN COMMERCIAL CLAIMS AND ENCOUNTERS DATABASE
    Witt, E.
    Kirkham, H.
    Baiano, R.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S563 - S563
  • [6] Cystic Fibrosis Foundation Pulmonary Guidelines Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis
    Ren, Clement L.
    Morgan, Rebecca L.
    Oermann, Christopher
    Resnick, Helaine E.
    Brady, Cynthia
    Campbell, Annette
    DeNagel, Richard
    Guill, Margaret
    Hoag, Jeffrey
    Lipton, Andrew
    Newton, Thomas
    Peters, Stacy
    Willey-Courand, Donna Beth
    Naureckas, Edward T.
    [J]. ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (03) : 271 - 280
  • [7] Cystic Fibrosis Transmembrane Conductance Regulator Modulators Reduce Hospitalizations for Acute Pancreatitis in Patients With Cystic Fibrosis
    Ramsey, M. L.
    Sobotka, L. A.
    Wellner, M. R.
    Porter, K.
    Lara, L. F.
    [J]. PANCREAS, 2020, 49 (10) : 1425 - 1426
  • [8] Cystic fibrosis transmembrane regulator haplotypes in households of patients with cystic fibrosis
    Furgeri, Daniela Tenorio
    Lima Marson, Fernando Augusto
    Araujo Correia, Cyntia Arivabeni
    Ribeiro, Jose Dirceu
    Bertuzzo, Carmen Silvia
    [J]. GENE, 2018, 641 : 137 - 143
  • [9] A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
    Wainwright, Claire E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 206 (10) : 1193 - 1195
  • [10] Effects of triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy on glucose metabolism in cystic fibrosis patients
    Yesquen, Pamela
    Campos, Ariadna
    Mogas, Eduard
    Yeste, Diego
    Gartnet, Silvia
    Clemente, Maria
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 201 - 201
12345